02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

LSX CEO Forum, London, England

June 27

American Society of Metabolic and Bariatric Surgery (ASMBS), New York City

June 14-16

Jefferies 2018 Healthcare Conference, New York City

June 5-8

2018 BIO international Convention, Boston, MA

June 4-7

American Society of Health-System Pharmacists (ASHP), Denver, CO

June 2-6

Bio€quity Europe, Ghent, Belgium

May 14-16

Society for Ambulatory Anesthesia (SAMBA), Miami, FL

May 3-5

American College of Obstetricins & Gynaecology (ACOG), Austin, TX

April 27-30

2018 World Congress on Regional Anesthesia & Pain Medicine (ASRA), New York City

April 19 - 21

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments

15 March 2018

BARHEMSYS™ (formerly BAREMSIS®) Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)

02 March 2018

Acacia Pharma - Prospectus

02 March 2018

Acacia Pharma Successfully Prices Its Initial Global Offering At Eur 3.60 Per Share Raising Eur 40 Million

19 February 2018

Acacia Pharma commences management roadshow and setting of the price range for its Initial Global Offering and listing on Euronext Brussels.

05 February 2018

Acacia Pharma Announces its Intention to Launch an Initial Global Offering and to List its Shares on Euronext Brussels

04 January 2018

FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV

13 February 2017

Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV

12 August 2016

Positive Results From Pivotal Phase 3 Trial Of BAREMSIS® For The Treatment Of PONV

21 March 2016

Initiation Of Second Pivotal Phase 3 Treatment Trial With BAREMSIS® In PONV

05 January 2016

Positive Results From Second Pivotal Phase 3 Prophylaxis Study Of BAREMSIS® In PONV

03 December 2015

Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman

06 May 2015

Positive Results From Phase 2 Study With APD403 In CINV

21 April 2015

Phase 3 Combination Prophylaxis Study Initiated With APD421 In PONV

03 March 2015

Scott Byrd and Christine Soden Appointed to Board of Directors